Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.48 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.43 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.40 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.40 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.40 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470091 | 0.96 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1TRAP1HPGDPIK3CA | |
| SCHEMBL5470286 | 0.88 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1TRAP1HPGDPIK3CA | |
| SCHEMBL5462346 | 0.87 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1TRAP1TP53HPGD | |
| SCHEMBL5472436 | 0.86 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1TRAP1HPGD | |
| SCHEMBL5466876 | 0.84 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1TRAP1HPGD | |
| SCHEMBL5467057 | 0.83 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1TRAP1HPGD | |
| SCHEMBL5474149 | 0.83 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1TRAP1HPGD | |
| SCHEMBL5457745 | 0.82 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1TRAP1HPGD | |
| SCHEMBL14582397 | 0.82 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL5464150 | 0.81 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1TRAP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | TK1, TK2, SLC1A5 | HSP90AA1 3373/4885HSP90AB1 3036/4885TRAP1 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.